抗内毒素治疗对肝硬化患者血管活性物质的影响

目的 探讨安全有效的抗内毒素疗法对肝炎后肝硬化失代偿期血浆一氧化氮（Ｒｉｔｒｉｃ ｏｘｉｄｅ，ＮＯ）、前列环素（６－Ｋｅｔｏ－ＰＧＦ１α），ＴＮＦ－α的影响。方法 观察了３０例肝硬化病人口服思密达脑阿尊西林抗内毒素治疗二周前后血浆内毒素，ＮＯ、６－Ｋｅｔｏ－ＰＧＦ１，ＴＮＦ－α水平变化情况及抗体功能状态与上述血管活性物质的关系。结果 肝硬化患者上述四种指标平均水平治疗前明显高于正常对照组，治疗二周

Effect of anti-endotoxin therapy on vaso-active substances in decompensated liver cirrhosis

Objective To study the anti-endotoxin therapy on the plasma levels of nitric oxide, prostacyclin, tumor necrosis factor- a in patients with liver cirrhosis after hepatitis. Methods Thirty patients with decompensated liver cirrho- sis accepted anti-endotoxin therapy with oral Amoxycillin and Smedta for 2 weeks. Plasma levels of endotoxin, nitric oxide, prostacyclin and tumor necrosis factor- a were detected before and after therapy in study group and control group, respectively. The relationship between endotoxin and vasoactive substances and between the four substances and the status of patients were analyzed. Results The four substances were all increased significantly(p < 0.01) in patients with liver cirrhosis compared with control group and decreased obviously after treatment for 2 weeks(endotoxin from 0.546 x 10~21 U/L to 0.347 x 10~21 U/L, no from 56.498 umol/L to 31.256 umol/L, 6-keto--PGF1a from 716.964 ng/L to 539.867ng/L, and TNF- a from 3.090 ug/L to 1.750 ug/L(P < 0.01). Conclusion The plasma levels of nitric oxide, prostacyclin and tumor necrosis factor- a increased because of endotoxemia. Amoxycillin and Smecta can clear endotoxin out effectively.